Optimal Treatment After Acute Myocardial Infarction in the Elderly

J. Herlitz,M. Hartford,M. Dellborg,B. Karlson

DOI: https://doi.org/10.2165/00002512-199506030-00002

1995-03-01

Drugs & Aging

Abstract:

What problem does this paper attempt to address?

Safety and Efficacy of Mechanical Thrombectomy in Elderly Patients with Acute Ischemic Stroke: A Single-Center Experience

Yuning Lu,Shanhu Xu,Rujie Zheng,Ning Ping Wang,Dongdong Lin,Yumiao Zhou,Chao Zheng,Yulin Li,Jiong Wu,Shu Wan,Ming Wang

DOI: https://doi.org/10.21203/rs.3.rs-2894293/v1

2023-01-01

Abstract:Abstract Background Mechanical thrombectomy (MT) has been established as the first-line treatment for acute ischemic stroke (AIS) from large vessel occlusions. However, the benefits of MT to the patients over 80 years old is not yet clear, for the elderly with AIS were usually excluded from large randomized controlled stroke clinical trials for their poor prognosis. Methods This study enrolled 187 adult patients with acute ischemic stroke from large vessel occlusions, including 53 patients ≥ 80 years old. Propensity score matching was used to match the patients༜80 years old with those ≥ 80 years old in a ratio of 1:1. The elderly patients were divided into bridging therapy subgroup and direct MT subgroup. The baseline characteristics and outcome were compared between younger patients and older patients, and elderly patients in two subgroups by multivariate logistic regression analysis. Results The good functional status at 90 days occurred in 44 (32.8%) younger patients, 12 (22.6%) in older patients, but the difference was not statistically significant (adjusted OR, 1.244[95%CI,0.520–2.882], P = 0.644). A higher mortality rate was observed in older patients (43% vs 16%, OR,0.245[95%CI,0.104–0.578], P = 0.001). After propensity score matching, the similar results were found in the good functional prognosis and mortality in the two groups. Moreover, in elderly patients, no significant difference was found in the outcome between the two subgroups. Conclusions Elderly patients with AIS from large vessel occlusions who received MT had similar good functional status and successful reperfusion to patients༜80 years old. MT is effective and relatively safe for the elderly.
Octogenarians, nonagenarians and centenarians with myocardial infarction over time in Sweden

D Venetsanos,L Desta,N Ekerstad,L Melbin,A Ravn-Fischer,C Pagonis,E Traff,J Persson,T Jernberg,J Alfredsson

DOI: https://doi.org/10.1093/eurheartj/ehae666.1492

IF: 39.3

2024-10-28

European Heart Journal

Abstract:Background The aim of this study was to evaluate temporal changes in baseline characteristics, in-hospital management and medication at discharge in very elderly with myocardial infarction (MI). Methods Between 2003 and 2016, we included all consecutive patients 80 years or-older, with a MI, included in the nationwide SWEDEHEART registry. The study period was divided into seven equal admission periods. Outcomes included major adverse cardiac and cerebrovascular events (MACCE, including death, MI or stroke) and net adverse cardiac and cerebrovascular events (NACCE, including MACCE and bleeding). All patients had complete 1-year follow up. To evaluate any potential associations between in-hospital management/medications at discharge and clinical outcomes, we adjusted for baseline characteristics and clinical presentation using multivariable Cox regression models. Results We included 85,054 patients. Over time, the proportion of patients with comorbidities such as hypertension, diabetes mellitus, prior percutaneous coronary intervention and a previous bleeding significantly increased but patients were less likely to have a prior MI and previous heart failure (HF). On arrival, the proportion of patients with acute HF declined. Invasive management significantly increased over time as well as prescription of evidence-based medication at discharge. At 1 year, the cumulative rate of MACCE and NACCE significantly decreased. We found a significantly lower risk for death, MI and stroke and a higher risk for bleeding. The observed differences remained significant after adjustment. We found no significant interaction between infarct type and outcomes. Conclusion During the study period, the prognosis in very elderly patients with MI substantially improved. In a population that has been excluded from randomised control trials, implementation of evidence-based management for patients with a MI, seemed to be associated with the lower risk for MACCE and NACCE over time.Cumulative rate of MACCE

cardiac & cardiovascular systems
Age related issues in reperfusion of myocardial infarction

Amelia Carro,Rachel Bastiaenen,Juan Carlos Kaski

DOI: https://doi.org/10.1007/s10557-011-6288-6

Abstract:Advances in pharmacological treatment and effective early myocardial revascularization have led to improved clinical outcomes in patients with acute myocardial infarction (AMI). However, it has been suggested that compared to younger subjects, elderly AMI patients are less likely to receive evidence-based treatment. Several reasons have been postulated to explain this trend, including uncertainty regarding the benefits of the commonly used interventions in the older age group as well as increased risk associated with comorbidities. The diagnosis, management, and post-hospitalization care of elderly patients presenting with an acute coronary syndrome (ACS) pose many difficulties at present due, at least in part, to the fact that trial data are scanty as elderly patients have been poorly represented in most clinical trials. Thus it appears that these high-risk individuals are often managed with more conservative strategies, compared to younger patients. This article reviews current evidence regarding management of AMI in the elderly.
Association of Use and Dose of Lipid-Lowering Therapy Post Acute Myocardial Infarction With 5-Year Survival in Older Adults

Antoine Fayol,François Schiele,Jean Ferrières,Etienne Puymirat,Vincent Bataille,Victoria Tea,Chekrallah Chamandi,Franck Albert,Gilles Lemesle,Guillaume Cayla,Orianne Weizman,Tabassome Simon,Nicolas Danchin,on behalf of the FAST-MI Investigators

DOI: https://doi.org/10.1161/circoutcomes.123.010685

2024-05-01

Circulation Cardiovascular Quality and Outcomes

Abstract:Circulation: Cardiovascular Quality and Outcomes, Ahead of Print. BACKGROUND:Older people are underrepresented in randomized trials. The association between lipid-lowering therapy (LLT) and its intensity after acute myocardial infarction and long-term mortality in this population deserves to be assessed.METHODS:The FAST-MI (French Registry of Acute ST-Elevation or Non-ST-Elevation Myocardial Infarction) program consists of nationwide French surveys including all patients admitted for acute myocardial infarction ≤48 hours from onset over a 1- to 2-month period in 2005, 2010, and 2015, with long-term follow-up. Numerous data were collected and a centralized 10-year follow-up was organized. The present analysis focused on the association between prescription of LLT (atorvastatin ≥40 mg or equivalent, or any combination of statin and ezetimibe) and 5-year mortality in patients aged ≥80 years discharged alive. Cox multivariable analysis and propensity score matching were used to adjust for baseline differences.RESULTS:Among the 2258 patients aged ≥80 years (mean age, 85±4 years; 51% women; 39% ST-segment elevation myocardial infarction; 58% with percutaneous coronary intervention), 415 were discharged without LLT (18%), 866 with conventional doses (38%), and 977 with high-dose LLT (43%). Five-year survival was 36%, 47.5%, and 58%, respectively. Compared with patients without LLT, high-dose LLT was significantly associated with lower 5-year mortality (adjusted hazard ratio, 0.78 [95% CI, 0.66–0.92]), whereas conventional-intensity LLT was not (adjusted hazard ratio, 0.93 [95% CI, 0.80–1.09]). In propensity score-matched cohorts (n=278 receiving high-intensity LLT and n=278 receiving no statins), 5-year survival was 52% with high-intensity LLT at discharge and 42% without statins (hazard ratio, 0.78 [95% CI, 0.62–0.98]).CONCLUSIONS:In these observational cohorts, high-intensity LLT at discharge after acute myocardial infarction was associated with reduced all-cause mortality at 5 years in an older adult population. These results suggest that high-intensity LLT should not be denied to patients on the basis of old age.REGISTRATION:URL:https://www.clinicaltrials.gov; Unique identifiers: NCT00673036, NCT01237418, and NCT02566200.

cardiac & cardiovascular systems
Invasive Treatment Strategy for Older Patients with Myocardial Infarction

Vijay Kunadian,Helen Mossop,Carol Shields,Michelle Bardgett,Philippa Watts,M Dawn Teare,Jonathan Pritchard,Jennifer Adams-Hall,Craig Runnett,David P Ripley,Justin Carter,Julie Quigley,Justin Cooke,David Austin,Jerry Murphy,Damian Kelly,James McGowan,Murugapathy Veerasamy,Dirk Felmeden,Hussain Contractor,Sanjay Mutgi,John Irving,Steven Lindsay,Gavin Galasko,Kelvin Lee,Ayyaz Sultan,Amardeep G Dastidar,Shazia Hussain,Iftikhar Ul Haq,Mark de Belder,Martin Denvir,Marcus Flather,Robert F Storey,David E Newby,Stuart J Pocock,Keith A A Fox,British Heart Foundation SENIOR-RITA Trial Team and Investigators

DOI: https://doi.org/10.1056/NEJMoa2407791

2024-11-07

Abstract:Background: Whether a conservative strategy of medical therapy alone or a strategy of medical therapy plus invasive treatment is more beneficial in older adults with non-ST-segment elevation myocardial infarction (NSTEMI) remains unclear. Methods: We conducted a prospective, multicenter, randomized trial involving patients 75 years of age or older with NSTEMI at 48 sites in the United Kingdom. The patients were assigned in a 1:1 ratio to a conservative strategy of the best available medical therapy or an invasive strategy of coronary angiography and revascularization plus the best available medical therapy. Patients who were frail or had a high burden of coexisting conditions were eligible. The primary outcome was a composite of death from cardiovascular causes (cardiovascular death) or nonfatal myocardial infarction assessed in a time-to-event analysis. Results: A total of 1518 patients underwent randomization; 753 patients were assigned to the invasive-strategy group and 765 to the conservative-strategy group. The mean age of the patients was 82 years, 45% were women, and 32% were frail. A primary-outcome event occurred in 193 patients (25.6%) in the invasive-strategy group and 201 patients (26.3%) in the conservative-strategy group (hazard ratio, 0.94; 95% confidence interval [CI], 0.77 to 1.14; P = 0.53) over a median follow-up of 4.1 years. Cardiovascular death occurred in 15.8% of the patients in the invasive-strategy group and 14.2% of the patients in the conservative-strategy group (hazard ratio, 1.11; 95% CI, 0.86 to 1.44). Nonfatal myocardial infarction occurred in 11.7% in the invasive-strategy group and 15.0% in the conservative-strategy group (hazard ratio, 0.75; 95% CI, 0.57 to 0.99). Procedural complications occurred in less than 1% of the patients. Conclusions: In older adults with NSTEMI, an invasive strategy did not result in a significantly lower risk of cardiovascular death or nonfatal myocardial infarction (the composite primary outcome) than a conservative strategy over a median follow-up of 4.1 years. (Funded by the British Heart Foundation; BHF SENIOR-RITA ISRCTN Registry number, ISRCTN11343602.).
Clinical Analysis of Elderly Acute Myocardial Infarction and Cardiogenic Shock after Coronary Intervention Treatment

YANG Chen,SUN Lei,WU Gui-jun,ZHAO Xin,HAN Ya-ling,JING Quan-min

DOI: https://doi.org/10.13241/j.cnki.pmb.2012.11.025

2012-01-01

Abstract:Objective: Comparative Analysis of interventional therapy and conservative treatment in elderly with cardiogenic shock complicating acute myocardial infarction.Methods: Retrospective analysis of elderly with cardiogenic shock complicating acute myocardial infarction was conducted in our hospital and 230 patients were enrolled.Patients were arranged to percutaneous coronary intervention group(PCI,120 patients) and conservative treatment group(CT,110 patients) according to the medical assessment of doctors.Then risk factors and efficacy of different treatment were analyzed.Results: History of myocardial infarction and history of heart failure were higher in conservative treatments group(24 % vs 20 % P0.05;25 % vs 17.3 %,P0.05),PCI decreased fatality in elderly with cardiogenic shock complicating acute myocardial infarction(40.8 % vs 71.8 %,P0.05).Meanwhile,conservative treatment group had more arrhythmia,lung infection and renal failure(26.7 % vs 21.8 %,P0.05;11.8 % vs 5.8 % P0.05;8.2 % vs 2.0 %,P0.05).Conclusion: Although has more complications compared to conservative treatment,PCI may significantly improved the prognosis in elderly with cardiogenic shock complicating acute myocardial infarction.
Acute cerebral infarction. Optimal management in older patients

P Langhorne,D J Stott

DOI: https://doi.org/10.2165/00002512-199506060-00004

Abstract:The optimal management of acute cerebral infarction requires consideration of the diagnosis, aetiology, identification of problems, general and specific aspects of care, and prevention of further vascular events. Stroke is a clinical diagnosis but cranial computed tomography (CT) scanning is invaluable to exclude the possibility of cerebral haemorrhage or where the diagnosis is uncertain. Good general care under a specialist multidisciplinary team can reduce mortality and the need for institutional care. Despite promising results from experimental studies, no routine drug therapies have yet shown clinical benefit in acute stroke. Several large trials are currently evaluating anticoagulant, antiplatelet, thrombolytic and neuroprotective agents. Many other proposed therapies have been subject to limited evaluation. Aspirin has a proven role in the prevention of further vascular events after a stroke or transient ischaemic attack. Warfarin, and to a lesser extent aspirin, can prevent recurrent events in patients with nonrheumatic atrial fibrillation. Concerns remain about the safety of warfarin in routine geriatric medical practice. The risk of recurrent stroke in patients with a symptomatic severe carotid artery stenosis is greatly reduced by endarterectomy.
The long-term clinical impact of high-intensity statin therapy in older patients with acute myocardial infarction

Y Kwon,N Kim,D H Kim,J S Park,Y J Park,B E Park,S Oh,H N Kim,S Y Jang,M H Bae,J H Lee,D H Yang,H S Park,Y Cho

DOI: https://doi.org/10.1093/eurheartj/ehae666.3130

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Introduction Despite substantial clinical evidence supporting the benefits of high-intensity statins for acute myocardial infarction, the clinical implications of their use in elderly populations have yet to be fully elucidated. Purpose This study aims to clarify the importance of high-intensity statin therapy at discharge for patients aged over 65 with acute myocardial infarction (AMI). Methods In this retrospective cohort analysis conducted with data from the Korean Acute Myocardial Infarction Registry (KAMIR), we evaluated 4,147 patients aged 65 and above who experienced acute myocardial infarction (AMI), underwent coronary interventions utilizing second-generation drug-eluting stents, and were prescribed statins at the time of discharge. The primary outcome was major adverse cardiovascular events (MACE) at 3 years, defined as the composite of all-cause deaths, any myocardial infarction, and any coronary revascularization. The secondary outcome was target-lesion failure (TLF), defined as the composite endpoint of all cardiac deaths, target vessel myocardial infarction, and ischemia-driven target lesion revascularization at 3 years. Results In this study, 1,268 patients (30.5%) were treated with high-intensity statins at discharge. The patients were stratified into two groups using an age threshold of 78 years. In the propensity-matched cohort aged 65 to 78, the use of high-intensity statins was associated with a significant reduction in MACE (19.1% versus 14.5%, p=0.011). In the propensity score-matched cohort aged over 78, however, treatment with high-intensity statins did not lead to a reduction in MACE (24.8% versus 24.5%, p>0.99). Additionally, multivariate analysis revealed that high-intensity statin therapy was associated with a reduced risk of MACE (HR 0.69, 95% CI [0.57-0.85], p<0.001) in patients aged 65 to 78. However, the effects of high-intensity statins on TLF were not significant in matched patients aged 65 to 78 (7.9% versus 6.5%, p=0.269) and in those aged over 78 (13.7% versus 12.1%, p=0.638). Conclusion This extensive, nationwide cohort study suggests that treatment with high-intensity statins upon discharge may not offer clinical benefits in reducing MACE and TLF in patients with AMI aged over 78, compared to those aged 65 to 78.

cardiac & cardiovascular systems
Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey

Annika Rosengren,Lars Wallentin,Maarten Simoons,Anselm K Gitt,Solomon Behar,Alexander Battler,David Hasdai

DOI: https://doi.org/10.1093/eurheartj/ehi774

IF: 39.3

2006-02-07

European Heart Journal

Abstract:AIMS: Age is one of the most powerful determinants of prognosis in myocardial infarction, but there is comparatively little recent data across the whole spectrum of acute coronary syndromes (ACS). We examined the impact of increasing age on clinical presentation and hospital outcome in a large sample of patients with ACS.METHODS AND RESULTS: Patients (n = 10 253) from the Euroheart ACS survey in 103 hospitals in 25 countries were investigated. There was a significant inverse association between the age and the likelihood of presenting with ST-elevation. For each decade of life, the odds of presenting with ST-elevation decreased by 0.82 [95% confidence interval (CI) 0.79-0.84]; P < 0.0001. Elderly patients were considerably less often treated by cardiologists, less extensively investigated, and, when presenting with ST-elevation ACS, less likely to be treated with reperfusion. Compared with patients <55 years, the odds ratios of hospital mortality were 1.87 (1.21-2.88) at age 55-64, 3.70 (2.51-5.44) at age 65-74, 6.23 (4.25-9.14) at age 75-84, and 14.5 (9.47-22.1) among patients > or =85 years, with no major differences across different types of admission or discharge diagnoses.CONCLUSION: Elderly ACS patients were less likely to present with ST-elevation but had substantial in-hospital mortality, yet they were markedly less intensively treated and investigated.

cardiac & cardiovascular systems
Guideline-Directed Medical Therapy for Elderly Patients With Acute Myocardial Infarction Who Undergo Percutaneous Coronary Intervention ― Insights From a Retrospective Observational Study ―

Kensaku Nishihira,Michikazu Nakai,Nehiro Kuriyama,Kosuke Kadooka,Yasuhiro Honda,Hiroki Emori,Keisuke Yamamoto,Shun Nishino,Takeaki Kudo,Kenji Ogata,Toshiyuki Kimura,Koichi Kaikita,Yoshisato Shibata

DOI: https://doi.org/10.1253/circj.cj-23-0837

2024-01-18

Circulation Journal

Abstract:BACKGROUND: The efficacy of guideline-directed medical therapy (GDMT) in the elderly remains unclear. This study evaluated the impact of GDMT (aspirin or a P2Y<sub>12</sub>inhibitor, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, β-blocker, and statin) at discharge on long-term mortality in elderly patients with acute myocardial infarction (AMI) who had undergone percutaneous coronary intervention (PCI).Methods and Results: Of 2,547 consecutive patients with AMI undergoing PCI in 2009-2020, we retrospectively analyzed 573 patients aged ≥80 years. The median follow-up period was 1,140 days. GDMT was prescribed to 192 (33.5%) patients at discharge. Compared with patients without GDMT, those with GDMT were younger and had higher rates of ST-segment elevation myocardial infarction and left anterior descending artery culprit lesion, higher peak creatine phosphokinase concentration, and lower left ventricular ejection fraction (LVEF). After adjusting for confounders, GDMT was independently associated with a lower cardiovascular death rate (hazard ratio [HR] 0.35; 95% confidence interval [CI] 0.16-0.81), but not with all-cause mortality (HR 0.77; 95% CI 0.50-1.18). In the subgroup analysis, the favorable impact of GDMT on cardiovascular death was significant in patients aged 80-89 years, with LVEF <50%, or with an estimated glomerular filtration rate ≥30 mL/min/1.73 m<sup>2</sup>.CONCLUSIONS: GDMT in patients with AMI aged ≥80 years undergoing PCI was associated with a lower cardiovascular death rate but not all-cause mortality.

cardiac & cardiovascular systems
Temporal trends in the treatment and outcome of nonagenarians with acute coronary syndrome

Ilya Losin,Ela Giladi,Ziad Arow,Ranin Hilu,Tal Ovdat,Abid Assali,David Pereg

DOI: https://doi.org/10.1097/mca.0000000000001427

2024-09-27

Coronary Artery Disease

Abstract:Background Nonagenarians are a fast-growing age group among acute coronary syndrome (ACS) patients. While new therapeutic options have improved outcomes of ACS patients, data regarding very elderly ACS patients are limited. We aimed to evaluate temporal trends in the treatment and outcomes of nonagenarian ACS patients. Methods Included were ACS patients aged below 90 years enrolled in ACS Israeli Survey. Patients were divided into two groups according to enrolment period: early (2000–2010) and recent (2012–2021). The primary endpoints were 30-day major adverse cardiovascular events and all-cause mortality. Secondary outcomes included in-hospital and 1-year all-cause mortality. Results Included were 316 elderly ACS patients. Of them, 184 were enrolled in the early and 132 in recent surveys. Patients enrolled in the recent period were more commonly referred for an invasive strategy and more commonly received guideline-based medical therapy. All-cause mortality at 30 days was significantly lower in the recent group compared with the early group (12.5 and 26.1%, respectively, P = 0.005). Rates of 30-day major adverse cardiovascular events were also significantly lower in the recent group (21.9 and 35.9%, respectively, P = 0.012). Patients in the recent group received more aggressive medical therapy in discharge but at 30-day follow-up, no difference in medical treatment was observed in the two groups. There were no significant differences in 1-year mortality rates. Conclusions Treatment of nonagenarians with ACS has improved over the past decade. Treatment improvement was associated with a significant improvement in 30-day outcomes without any effect in 1 year. Nevertheless, even with contemporary treatment, nonagenarians with ACS remain a high-risk group with high mortality rates.

cardiac & cardiovascular systems
Acute Coronary Syndrome in Octogenarians, Association Between Percutaneous Coronary Intervention and Long-Term Mortality

Salim Bary Barywani,Shijun Li,Maria Lindh,Josefin Ekelund,Max Petzold,Per Albertsson,Lars H. Lund,Michael L. X. Fu

DOI: https://doi.org/10.2147/cia.s89127

IF: 3.829

2015-01-01

Clinical Interventions in Aging

Abstract:Aim: Evidence of improved survival after use of percutaneous coronary intervention (PCI) in elderly patients with acute coronary syndrome (ACS) is limited. We assessed the association between PCI and long-term mortality in octogenarians with ACS.Methods and results: We followed 353 consecutive patients aged >= 80 years hospitalized with ACS during 2006-2007. Among them, 182 were treated with PCI, whereas 171 were not. PCI-treated patients were younger and more often male, and had less stroke and dependency in activities of daily living, but there were no significant differences in occurrence of diabetes mellitus, chronic obstructive pulmonary disease, hypertension, and uncured malignancies between the two groups. The association between PCI and all-cause mortality was assessed in the overall cohort and a 1: 1 matched cohort based on propensity score (PS). In overall cohort, 5-year all-cause mortality was 46.2% and 89.5% in the PCI and non-PCI groups, respectively. Cox regression analysis in overall cohort by adjustment for ten baseline variables showed statistically significant association between PCI and reduced long-term mortality (P < 0.001, hazard ratio 0.4, 95% confidence interval [CI] 0.2-0.5). In propensity-matched cohort, 5-year all-cause mortality was 54.9% and 83.1% in the PCI and non-PCI groups, respectively. Kaplan-Meier survival curves and log rank test showed significantly improved mean survival rates (P=0.001): 48 months (95% CI 41-54) for PCI-treated patients versus 35 months (95% CI 29-42) for non-PCI-treated patients. Furthermore, by performing Cox regression analysis, PCI was still associated with reduced long-term mortality (P=0.029, hazard ratio 0.5, 95% CI 0.3-0.9) after adjustment for PS and confounders: age, male sex, cognitive deterioration, uncured malignancies, left ventricular ejection fraction <45%, estimated glomerular filtration rate < 35 mL/min, ST-segment elevation myocardial infarction, mitral regurgitation, and medication at discharge with clopidogrel and statins.Conclusion: In octogenarians with ACS, PCI was associated with improved survival from all-cause death over 5 years of follow-up.
[Late sequelae and complications of electron therapy].

N. D. Tapley,G. Fletcher,F. Eschwège,J. Horiot

1971-10-01

Abstract:
Lipid lowering therapy in patients aged 90 years or older with acute myocardial infarction:a multicenter cohort study

L K Huo,S T Hu,T S Gu,Y K Zhang,C Jiang,J K Zhang,X Wu,X Liu,T Liu,K Y Chen

DOI: https://doi.org/10.1093/eurheartj/ehae666.3139

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background Lipid-lowing therapy significantly reduce adverse cardiovascular events in patients with acute myocardial infarction (AMI). However, evidence regarding the efficacy of lipid-lowing therapy in extremely elderly patients with AMI is limited. Purpose This study aims to evaluate major adverse cardiovascular events (MACCE) at 1 year in relation to taking lipid-lowing therapy (statins) among patients aged 90 years or older. Methods The data for this study were derived from a retrospective cohort comprising patients admitted to secondary or tertiary hospitals from 2010 to 2023. Patients were grouped by lipid-lowing therapy: statins group (n=549) and not taking statins group (n=811). The primary endpoint was MACCE, a composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke, at 1 year. Secondary endpoints included cardiac death (CD), stroke, and recurrence of myocardial infarction at 1 year. Inverse probability treatment weighting (IPTW) based on propensity scores was performed to balance baseline characteristics. A multivariate adjusted Cox proportional hazard model evaluated the association between lipid-lowing therapy and clinical endpoints. Results Of the 1,360 patients, 77.2% were men, and the median age was 92 years. During 1 year follow up, 35.3% of patients experienced MACCE, and 28.7% died due to CD. After IPTW, the incidence of MACCE was lower in the statins group compared to the non-statins group (33.3% vs. 42.6%, p=0.036), as was 1- year mortality due to CD (26.2% vs.35.9%, p=0.021). However, there were no differences in the incidence of stroke (2.8% vs. 4.5%, p>0.274) or recurrence of myocardial infarction (4.7% vs. 5.1%, p=0,855) at 1 year. Kaplan-Meier analysis showed a lower probability of 1-year MACCE and CD in the statins group (log-rank test, p<0.001). Multivariate Cox regression analysis demonstrated that statin therapy reduced the incidence of MACCE (aHR 0.67; 95%CI, 0.40–0.91; p=0.009) and 1-year CD (aHR 0.63; 95%CI, 0.45–0.87; p=0.005). Conclusions Lipid-lowering therapy with statins was associated with a significantly lower risk of 1-year MACEE and cardiac death in elderly patients aged over 90 years with AMI. These findings support the use of lipid-lowing therapy in elderly individuals.

cardiac & cardiovascular systems
Reperfusion Therapy And Antithrombotic Treatments In Patients 75 Years And Older With St-Segment Elevation Myocardial Infarction In China: Findings From The Ccc-Acs Project

Mengge Zhou,Jing Liu,Yongchen Hao,Gregg C. Fonarow,Junbo Ge,Kathryn A. Taubert,Louise Morgan,Chang-Sheng Ma,Yaling Han,Sidney C. Smith,Yong Huo,Dong Zhao

DOI: https://doi.org/10.1016/j.jacc.2018.08.536

IF: 24

2018-01-01

Journal of the American College of Cardiology

Abstract:With population aging and the extension of life expectancy, the proportion of patients ≥ 75 years of age with ST-segment elevation myocardial infarction (STEMI) is expected to increase. As these elderly patients are at high risk of both ischemia and bleeding, giving the appropriate treatment to
Acute coronary syndrome in elderly: aspects of patient management

Yu. D. Ryzhkova,E. V. Kanareykina,M. R. Atabegashvili,E. V. Konstantinova,M. Yu. Gilyarov

DOI: https://doi.org/10.17650/1818-8338-2019-13-1-2-19-26

2019-08-25

The Clinician

Abstract:Coronary heart disease is the leading cause of death worldwide. Over the past few decades, life expectancy has increased, which has led to an aging population in developed countries, so the average age of patients with acute coronary syndrome (ACS) has steadily increased in recent decades. The inclusion of elderly and senile patients in randomized clinical trials does not reflect the age-related association of these diseases. However, antithrombotic therapy and interventional treatment are the basis of treatment in patients with ACS of any age, including the elderly. For older patients, there may be a mismatch between chronological and biological age. The question of how close the treatment of elderly patients with ACS is to the level of current recommendations and whether it is possible to apply them unconditionally in this group of patients does not have a definite answer. Current recommendations and the underlying randomized clinical trials are focused on any one disease, whereas in the elderly in most cases multimorbid pathology occurs. In general, elderly patients with ACS should be treated using the same methods as younger patients, however, the presence of comorbid diseases in an elderly patient naturally increases the risk of complications, makes the patient’s prognosis heavier, significantly affects treatment tactics, limits the possibility of using conventional approaches when choosing a drug therapy.
The long-term clinical benefit of early versus delayed invasive strategies in elderly patients with non-ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention

J C Choe,M S Kim,S H Lee,J H Ahn,H W Lee,J H Oh,J H Choi,H C Lee,K S Cha,M H Jeong

DOI: https://doi.org/10.1093/eurheartj/ehae666.3138

IF: 39.3

2024-10-30

European Heart Journal

Abstract:Background The data regarding long-term outcomes of early versus delayed invasive strategies in elderly patients who have undergone percutaneous coronary intervention (PCI) for non-ST-segment elevation myocardial infarction (NSTEMI) is limited. Purpose We aimed to investigate the long-term clinical benefit of early versus delayed invasive strategies in elderly patients who underwent PCI for NSTEMI. Methods From a nationwide, prospective, real-world registry of 13,104 patients with acute myocardial infarction (MI) who underwent PCI, 2818 elderly patients (aged ≥70 years) who underwent PCI for NSTEMI were included. Of these, 2299 patients were treated with an early invasive strategy (early invasive group), and 519 were treated later (delayed invasive group). The incidence of major adverse cardiac events (MACE; all-cause death, recurrent MI, any revascularization, stroke, readmission due to heart failure [HF], or definite/probable stent thrombosis [ST]) and the components of MACE were compared using multivariable Cox regression, propensity score (PS) matched, and PS-adjusted analyses. Results During a median follow-up of 1047 days, MACE, all-cause death, and cardiac death occurred in 1018 (36.1%), 660 (23.4%), and 423 patients (15.0%), respectively. The early invasive group showed significantly lower risks of MACE (entire: 35.0% vs. 41.2%, hazard ratio [HR] 0.77, 95% confidence interval [CI] 0.66-0.90, p=0.001; PS-matched: n=984, 33.3% vs. 40.8%, HR 0.75, 95% CI 0.62-0.91, p=0.005), all-cause death (entire: 22.5% vs. 27.4%, HR 0.76, 95% CI 0.63-0.92, p=0.004; PS-matched: 21.8% vs. 27.2%, HR 0.75, 95% CI 0.58-0.90, p=0.005), cardiac death (entire: 13.8% vs. 20.2%, HR 0.64, 95% CI 0.51-0.79, p<0.001; PS-matched: 13.1% vs. 19.4%, HR 0.67, 95% CI 0.55-0.86, p=0.011), and readmission due to HF (entire: 6.5% vs. 9.2%, HR 0.64, 95% CI 0.46-0.89, p=0.007; PS-matched: 6.7% vs. 9.4%, HR 0.68, 95% CI 0.51-0.96, p=0.017) than the delayed invasive group. There were no significant differences in the risks of recurrent MI, any revascularization, stroke, and definite/probable ST between the groups. Furthermore, in patients aged ≥80 years, the early invasive group had significantly reduced rates of MACE (42.9% vs. 49.5%, HR 0.71, 95% CI 0.55-0.91, p=0.039), all-cause death (31.7% vs. 39.0%, HR 0.71, 95% CI 0.55-0.92, p=0.010), and cardiac death (20.9% vs. 31.0%, HR 0.59, 95% CI 0.44-0.80, p=0.001) compared to the delayed invasive group. Conclusions In elderly patients with NSTEMI, an early invasive intervention strategy was associated with favorable long-term clinical outcomes compared to a delayed invasive intervention strategy.

cardiac & cardiovascular systems
Invasive Treatment Strategy in Adults With Frailty and NSTEMI

Juan Sanchis,Héctor Bueno,Sergio García-Blas,Oriol Alegre,David Martí,Manuel Martínez-Sellés,Laura Domínguez-Pérez,Pablo Díez-Villanueva,Jose A. Barrabés,Francisco Marín,Adolfo Villa,Marcelo Sanmartín,Cinta Llibre,Alessandro Sionís,Antoni Carol,Agustín Fernández-Cisnal,Elena Calvo,María José Morales,Jaime Elízaga,Iván Gómez,Fernando Alfonso,Bruno García del Blanco,Francesc Formiga,Eduardo Núñez,Julio Núñez,Albert Ariza-Solé

DOI: https://doi.org/10.1001/jamanetworkopen.2024.0809

2024-03-07

JAMA Network Open

Abstract:This extended follow-up of a randomized clinical trial investigates whether restricted mean survival time differs among patients with frailty who undergo intensive vs conservative treatment for acute non–ST-segment elevation myocardial infarction.

medicine, general & internal
Optimal duration of medical therapy for patients with acute myocardial infarction

Ki Yung Boo,Seung-Jae Joo,Jae-Geun Lee,Joon-Hyouk Choi,Song-Yi Kim,Geum Ko,Hae Eun Yun,Myung Ho Jeong,on behalf of the KAMIR-NIH investigators

DOI: https://doi.org/10.1097/md.0000000000040697

IF: 1.6

2024-12-01

Medicine

Abstract:Acute myocardial infarction (AMI) is the primary cause of cardiac mortality and morbidity worldwide. [ 1 , 2 ] It necessitates evidence-based, long-term medical treatment to reduce future cardiovascular events following optimal initial reperfusion therapy. Beta-blockers (BB), inhibitors of the renin-angiotensin system (RAS), and statins are the 3 mainstream medications recommended for patients with AMI. [ 3–7 ] However, the optimal duration of these medications has not been clearly demonstrated in the randomized clinical trials, leading to the inconsistent recommendations.

medicine, general & internal
Comparison of In-Hospital Outcomes of Invasive and Non-Invasive Treatments in Elderly Patients with Acute Myocardial Infarction

李毅,韩雅玲,荆全民,王守力,王效增

DOI: https://doi.org/10.3969/j.issn.1009-7236.2004.03.020

2004-01-01

Abstract:AIM: To compare the in-hospital outcomes of elderly patients with acute myocardial infarction(AMI) treated by invasive or non-invasive protocol. METHODS:133 consecutive patients hospitalized for AMI were registered, including 76 patients who underwent emergency percutaneous coronary intervention(PCI) within 24 h after the onset of AMI and 57 patients who received conservative non-invasive therapies. Clinical characteristics and in-hosptial adverse cardiac event rates of these two divisions were analyzed. RESULTS: In the invasive group, success rate of patients and lesions was 99% and 98% respectively, procedure related complication occurred in 4 cases(5%), and no patient died during the operative procedures. Invasive group had a lower in-hospital mortality (11% vs 25%, P0.05) and total adverse cardiac event rates (17% vs 44%,P0.01) compared with non-invasive group. There were no significant differences in the average hospitalized duration between the two groups. The CCU duration of the invasive group was shorter than that of the non-invasive group (4±5 d vs 8±6 d, P0.01). CONCLUSION: In elderly AMI patients, invasive treatment can significantly decrease in-hospital mortality and adverse cardiac event rate compared with non-invasive treatment, thus gaining a better short-term outcome.

Optimal Treatment After Acute Myocardial Infarction in the Elderly

Safety and Efficacy of Mechanical Thrombectomy in Elderly Patients with Acute Ischemic Stroke: A Single-Center Experience

Octogenarians, nonagenarians and centenarians with myocardial infarction over time in Sweden

Age related issues in reperfusion of myocardial infarction

Association of Use and Dose of Lipid-Lowering Therapy Post Acute Myocardial Infarction With 5-Year Survival in Older Adults

Invasive Treatment Strategy for Older Patients with Myocardial Infarction

Clinical Analysis of Elderly Acute Myocardial Infarction and Cardiogenic Shock after Coronary Intervention Treatment

Acute cerebral infarction. Optimal management in older patients

The long-term clinical impact of high-intensity statin therapy in older patients with acute myocardial infarction

Age, clinical presentation, and outcome of acute coronary syndromes in the Euroheart acute coronary syndrome survey

Guideline-Directed Medical Therapy for Elderly Patients With Acute Myocardial Infarction Who Undergo Percutaneous Coronary Intervention ― Insights From a Retrospective Observational Study ―

Temporal trends in the treatment and outcome of nonagenarians with acute coronary syndrome

Acute Coronary Syndrome in Octogenarians, Association Between Percutaneous Coronary Intervention and Long-Term Mortality

[Late sequelae and complications of electron therapy].

Lipid lowering therapy in patients aged 90 years or older with acute myocardial infarction:a multicenter cohort study

Reperfusion Therapy And Antithrombotic Treatments In Patients 75 Years And Older With St-Segment Elevation Myocardial Infarction In China: Findings From The Ccc-Acs Project

Acute coronary syndrome in elderly: aspects of patient management

The long-term clinical benefit of early versus delayed invasive strategies in elderly patients with non-ST-segment elevation myocardial infarction who have undergone percutaneous coronary intervention

Invasive Treatment Strategy in Adults With Frailty and NSTEMI

Optimal duration of medical therapy for patients with acute myocardial infarction

Comparison of In-Hospital Outcomes of Invasive and Non-Invasive Treatments in Elderly Patients with Acute Myocardial Infarction